{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T04:04:22Z","timestamp":1769832262378,"version":"3.49.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,28]],"date-time":"2025-12-28T00:00:00Z","timestamp":1766880000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T00:00:00Z","timestamp":1769731200000},"content-version":"vor","delay-in-days":33,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100014718","name":"Innovative Research Group Project of the National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82370776"],"award-info":[{"award-number":["82370776"]}],"id":[{"id":"10.13039\/100014718","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Outstanding Scientific Research and Innovation Team for Male Genitourinary Diseases in Anhui Provincial Universities"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"DOI":"10.1007\/s12672-025-04355-5","type":"journal-article","created":{"date-parts":[[2025,12,28]],"date-time":"2025-12-28T18:32:40Z","timestamp":1766946760000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["hsa-miR-145-3p defines a fibro-inflammatory bladder cancer subtype with distinct therapeutic vulnerabilities"],"prefix":"10.1007","volume":"17","author":[{"given":"Muyang","family":"Xu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shaoyu","family":"Yue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ziqi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rongrong","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chaozhao","family":"Liang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,28]]},"reference":[{"issue":"3","key":"4355_CR1","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"CA Cancer J Clin"},{"key":"4355_CR2","doi-asserted-by":"publisher","first-page":"2565","DOI":"10.1100\/2011\/251920","volume":"11","author":"AK Kader","year":"2011","unstructured":"Kader AK. Bladder cancer. Sci World J. 2011;11:2565\u20136.","journal-title":"Sci World J"},{"key":"4355_CR3","doi-asserted-by":"publisher","DOI":"10.3390\/medsci8010015","author":"K Saginala","year":"2020","unstructured":"Saginala K, Barsouk A, Aluru JS, et al. Epidemiology of bladder cancer. Med Sci. 2020. https:\/\/doi.org\/10.3390\/medsci8010015.","journal-title":"Med Sci"},{"issue":"1","key":"4355_CR4","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1002\/path.4886","volume":"242","author":"G Sj\u00f6dahl","year":"2017","unstructured":"Sj\u00f6dahl G, Eriksson P, Liedberg F, et al. Molecular classification of urothelial carcinoma: global mRNA classification versus tumour-cell phenotype classification. J Pathol. 2017;242(1):113\u201325.","journal-title":"J Pathol"},{"issue":"2","key":"4355_CR5","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.eururo.2012.07.033","volume":"63","author":"M Burger","year":"2013","unstructured":"Burger M, Catto JW, Dalbagni G, et al. Epidemiology and risk factors of urothelial bladder cancer. Eur Urol. 2013;63(2):234\u201341.","journal-title":"Eur Urol"},{"issue":"2","key":"4355_CR6","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.ajur.2015.04.016","volume":"2","author":"K Li","year":"2015","unstructured":"Li K, Lin T, Xue W, et al. Current status of diagnosis and treatment of bladder cancer in China\u2014analyses of Chinese Bladder Cancer Consortium database. Asian J Urol. 2015;2(2):63\u20139.","journal-title":"Asian J Urol"},{"issue":"3","key":"4355_CR7","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.annonc.2021.11.012","volume":"33","author":"T Powles","year":"2022","unstructured":"Powles T, Bellmunt J, Comperat E, et al. Bladder cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up\u2606. Ann Oncol. 2022;33(3):244\u201358.","journal-title":"Ann Oncol"},{"issue":"5","key":"4355_CR8","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1016\/j.eururo.2019.08.016","volume":"76","author":"M Babjuk","year":"2019","unstructured":"Babjuk M, Burger M, Comp\u00e9rat EM, et al. European Association of urology guidelines on non-muscle-invasive bladder cancer (TaT1 and carcinoma in situ)\u20142019 update. Eur Urol. 2019;76(5):639\u201357.","journal-title":"Eur Urol"},{"issue":"1","key":"4355_CR9","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.eururo.2020.03.055","volume":"79","author":"JA Witjes","year":"2021","unstructured":"Witjes JA, Bruins HM, Cathomas R, et al. European association of urology guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2020 guidelines. Eur Urol. 2021;79(1):82\u2013104.","journal-title":"Eur Urol"},{"issue":"2","key":"4355_CR10","doi-asserted-by":"publisher","first-page":"505","DOI":"10.7150\/ijms.49228","volume":"18","author":"X Zheng","year":"2021","unstructured":"Zheng X, Qiu S, Yang L, et al. Comparison of survival outcomes between primary and secondary muscle-invasive bladder cancer: an updated meta-analysis. Int J Med Sci. 2021;18(2):505\u201310.","journal-title":"Int J Med Sci"},{"issue":"3","key":"4355_CR11","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1016\/j.eururo.2005.12.031","volume":"49","author":"RJ Sylvester","year":"2006","unstructured":"Sylvester RJ, Van Der Meijden AP, Oosterlinck W, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol. 2006;49(3):466\u20135 (discussion 475-7).","journal-title":"Eur Urol"},{"issue":"1","key":"4355_CR12","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/S0022-5347(05)67972-4","volume":"163","author":"HW Herr","year":"2000","unstructured":"Herr HW. Tumor progression and survival of patients with high grade, noninvasive papillary (TaG3) bladder tumors: 15-year outcome. J Urol. 2000;163(1):60\u20131 (discussion 61-2).","journal-title":"J Urol"},{"issue":"1","key":"4355_CR13","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1038\/s41598-018-19199-z","volume":"8","author":"MCS Wong","year":"2018","unstructured":"Wong MCS, Fung FDH, Leung C, et al. The global epidemiology of bladder cancer: a joinpoint regression analysis of its incidence and mortality trends and projection. Sci Rep. 2018;8(1):1129.","journal-title":"Sci Rep"},{"key":"4355_CR14","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2023-076743","volume":"384","author":"A Lopez-Beltran","year":"2024","unstructured":"Lopez-Beltran A, Cookson MS, Guercio BJ, et al. Advances in diagnosis and treatment of bladder cancer. BMJ. 2024;384:e076743.","journal-title":"BMJ"},{"issue":"10061","key":"4355_CR15","doi-asserted-by":"publisher","first-page":"2796","DOI":"10.1016\/S0140-6736(16)30512-8","volume":"388","author":"AM Kamat","year":"2016","unstructured":"Kamat AM, Hahn NM, Efstathiou JA, et al. Bladder cancer. Lancet. 2016;388(10061):2796\u2013810.","journal-title":"Lancet"},{"issue":"6","key":"4355_CR16","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1111\/bju.14045","volume":"120","author":"NI Guidance","year":"2017","unstructured":"Guidance NI. Bladder cancer: diagnosis and management of bladder cancer: \u00a9 NICE (2015) Bladder cancer: diagnosis and management of bladder cancer. BJU Int. 2017;120(6):755\u201365.","journal-title":"BJU Int."},{"issue":"2","key":"4355_CR17","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/S0302-2838(01)00026-4","volume":"41","author":"W Oosterlinck","year":"2002","unstructured":"Oosterlinck W, Lobel B, Jakse G, et al. Guidelines on bladder cancer. Eur Urol. 2002;41(2):105\u201312.","journal-title":"Eur Urol"},{"issue":"2","key":"4355_CR18","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.hoc.2014.10.013","volume":"29","author":"M Sun","year":"2015","unstructured":"Sun M, Trinh QD. Diagnosis and staging of bladder cancer. Hematol Oncol Clin North Am. 2015;29(2):205\u201318.","journal-title":"Hematol Oncol Clin North Am"},{"issue":"3","key":"4355_CR19","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1097\/CCO.0b013e3282f8b03e","volume":"20","author":"DA Barocas","year":"2008","unstructured":"Barocas DA, Clark PE. Bladder cancer. Curr Opin Oncol. 2008;20(3):307\u201314.","journal-title":"Curr Opin Oncol"},{"issue":"1","key":"4355_CR20","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.urolonc.2020.08.016","volume":"39","author":"K Ng","year":"2021","unstructured":"Ng K, Stenzl A, Sharma A, et al. Urinary biomarkers in bladder cancer: a review of the current landscape and future directions. Urol Oncol. 2021;39(1):41\u201351.","journal-title":"Urol Oncol"},{"issue":"2","key":"4355_CR21","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1148\/rg.322115125","volume":"32","author":"S Verma","year":"2012","unstructured":"Verma S, Rajesh A, Prasad SR, et al. Urinary bladder cancer: role of MR imaging. Radiographics. 2012;32(2):371\u201387.","journal-title":"Radiographics"},{"issue":"3","key":"4355_CR22","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.eururo.2016.05.041","volume":"71","author":"M Babjuk","year":"2017","unstructured":"Babjuk M, B\u00f6hle A, Burger M, et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2016. Eur Urol. 2017;71(3):447\u201361.","journal-title":"Eur Urol"},{"issue":"6","key":"4355_CR23","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1634\/theoncologist.2015-0440","volume":"21","author":"M Yin","year":"2016","unstructured":"Yin M, Joshi M, Meijer RP, et al. Neoadjuvant chemotherapy for muscle-invasive bladder cancer: a systematic review and two-step meta-analysis. Oncologist. 2016;21(6):708\u201315.","journal-title":"Oncologist"},{"issue":"4","key":"4355_CR24","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1080\/21681805.2019.1624611","volume":"53","author":"B Russell","year":"2019","unstructured":"Russell B, Sherif A, H\u00e4ggstr\u00f6m C, et al. Neoadjuvant chemotherapy for muscle invasive bladder cancer: a nationwide investigation on survival. Scand J Urol. 2019;53(4):206\u201312.","journal-title":"Scand J Urol"},{"issue":"3","key":"4355_CR25","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1111\/iju.14749","volume":"29","author":"D Gopalakrishnan","year":"2022","unstructured":"Gopalakrishnan D, Elsayed AS, Hussein AA, et al. Impact of neoadjuvant chemotherapy on survival and recurrence patterns after robot-assisted radical cystectomy for muscle-invasive bladder cancer: results from the International Robotic Cystectomy Consortium. Int J Urol. 2022;29(3):197\u2013205.","journal-title":"Int J Urol"},{"issue":"1","key":"4355_CR26","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1111\/bju.14211","volume":"122","author":"CO Mmeje","year":"2018","unstructured":"Mmeje CO, Benson CR, Nogueras-Gonz\u00e1lez GM, et al. Determining the optimal time for radical cystectomy after neoadjuvant chemotherapy. BJU Int. 2018;122(1):89\u201398.","journal-title":"BJU Int"},{"issue":"7","key":"4355_CR27","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/S1470-2045(21)00147-9","volume":"22","author":"AV Balar","year":"2021","unstructured":"Balar AV, Kamat AM, Kulkarni GS, et al. Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study. Lancet Oncol. 2021;22(7):919\u201330.","journal-title":"Lancet Oncol"},{"issue":"11","key":"4355_CR28","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","volume":"376","author":"J Bellmunt","year":"2017","unstructured":"Bellmunt J, De Wit R, Vaughn DJ, et al. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med. 2017;376(11):1015\u201326.","journal-title":"N Engl J Med"},{"issue":"10236","key":"4355_CR29","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1016\/S0140-6736(20)30230-0","volume":"395","author":"MD Galsky","year":"2020","unstructured":"Galsky MD, Arija J\u00c1A, Bamias A, et al. Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial. Lancet. 2020;395(10236):1547\u201357.","journal-title":"Lancet"},{"issue":"10122","key":"4355_CR30","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1016\/S0140-6736(17)33297-X","volume":"391","author":"T Powles","year":"2018","unstructured":"Powles T, Dur\u00e1n I, Van Der Heijden MS, et al. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2018;391(10122):748\u201357.","journal-title":"Lancet"},{"issue":"11","key":"4355_CR31","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1016\/S1470-2045(16)30496-X","volume":"17","author":"P Sharma","year":"2016","unstructured":"Sharma P, Callahan MK, Bono P, et al. Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1\/2 trial. Lancet Oncol. 2016;17(11):1590\u20138.","journal-title":"Lancet Oncol"},{"issue":"7","key":"4355_CR32","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1634\/theoncologist.2014-0422","volume":"20","author":"GK Pennock","year":"2015","unstructured":"Pennock GK, Chow LQ. The evolving role of immune checkpoint inhibitors in cancer treatment. Oncologist. 2015;20(7):812\u201322.","journal-title":"Oncologist"},{"issue":"7","key":"4355_CR33","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1016\/j.trecan.2020.02.003","volume":"6","author":"J Cao","year":"2020","unstructured":"Cao J, Yan Q. Cancer epigenetics, tumor immunity, and immunotherapy. Trends Cancer. 2020;6(7):580\u201392.","journal-title":"Trends Cancer"},{"issue":"2","key":"4355_CR34","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/S0092-8674(04)00045-5","volume":"116","author":"DP Bartel","year":"2004","unstructured":"Bartel DP. Micrornas: genomics, biogenesis, mechanism, and function. Cell. 2004;116(2):281\u201397.","journal-title":"Cell"},{"issue":"2","key":"4355_CR35","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.cell.2009.01.002","volume":"136","author":"DP Bartel","year":"2009","unstructured":"Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell. 2009;136(2):215\u201333.","journal-title":"Cell"},{"key":"4355_CR36","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1146\/annurev-pathol-012513-104715","volume":"9","author":"G Di Leva","year":"2014","unstructured":"Di Leva G, Garofalo M, Croce CM. Micrornas in cancer. Annu Rev Pathol. 2014;9:287\u2013314.","journal-title":"Annu Rev Pathol"},{"issue":"2","key":"4355_CR37","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1002\/ijc.24390","volume":"125","author":"T Ichimi","year":"2009","unstructured":"Ichimi T, Enokida H, Okuno Y, et al. Identification of novel microrna targets based on microrna signatures in bladder cancer. Int J Cancer. 2009;125(2):345\u201352.","journal-title":"Int J Cancer"},{"issue":"12","key":"4355_CR38","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1038\/nrurol.2016.193","volume":"13","author":"A Fendler","year":"2016","unstructured":"Fendler A, Stephan C, Yousef GM, et al. The translational potential of microRNAs as biofluid markers of urological tumours. Nat Rev Urol. 2016;13(12):734\u201352.","journal-title":"Nat Rev Urol"},{"issue":"2","key":"4355_CR39","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.clgc.2012.01.001","volume":"10","author":"G Wang","year":"2012","unstructured":"Wang G, Chan ES, Kwan BC, et al. Expression of micrornas in the urine of patients with bladder cancer. Clin Genitourin Cancer. 2012;10(2):106\u201313.","journal-title":"Clin Genitourin Cancer"},{"issue":"5","key":"4355_CR40","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1038\/sj.bjc.6605570","volume":"102","author":"T Chiyomaru","year":"2010","unstructured":"Chiyomaru T, Enokida H, Tatarano S, et al. miR-145 and miR-133a function as tumour suppressors and directly regulate FSCN1 expression in bladder cancer. Br J Cancer. 2010;102(5):883\u201391.","journal-title":"Br J Cancer"},{"issue":"3","key":"4355_CR41","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0018286","volume":"6","author":"Y Han","year":"2011","unstructured":"Han Y, Chen J, Zhao X, et al. Microrna expression signatures of bladder cancer revealed by deep sequencing. PLoS ONE. 2011;6(3):e18286.","journal-title":"PLoS ONE"},{"issue":"5","key":"4355_CR42","first-page":"6355","volume":"16","author":"H Zhang","year":"2018","unstructured":"Zhang H, Jiang M, Liu Q, et al. Mir-145-5p inhibits the proliferation and migration of bladder cancer cells by targeting TAGLN2. Oncol Lett. 2018;16(5):6355\u201360.","journal-title":"Oncol Lett"},{"key":"4355_CR43","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13092053","author":"CM Neophytou","year":"2021","unstructured":"Neophytou CM, Panagi M, Stylianopoulos T, et al. The role of tumor microenvironment in cancer metastasis: molecular mechanisms and therapeutic opportunities. Cancers (Basel). 2021. https:\/\/doi.org\/10.3390\/cancers13092053.","journal-title":"Cancers (Basel)"},{"issue":"5","key":"4355_CR44","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1007\/s00345-020-03474-8","volume":"39","author":"JL Pfail","year":"2021","unstructured":"Pfail JL, Katims AB, Alerasool P, et al. Immunotherapy in non-muscle-invasive bladder cancer: current status and future directions. World J Urol. 2021;39(5):1319\u201329.","journal-title":"World J Urol"},{"issue":"10","key":"4355_CR45","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1111\/jcmm.12358","volume":"18","author":"SY Cui","year":"2014","unstructured":"Cui SY, Wang R, Chen LB. Microrna-145: a potent tumour suppressor that regulates multiple cellular pathways. J Cell Mol Med. 2014;18(10):1913\u201326.","journal-title":"J Cell Mol Med"},{"issue":"1","key":"4355_CR46","doi-asserted-by":"publisher","first-page":"S60","DOI":"10.4111\/icu.2016.57.S1.S60","volume":"57","author":"H Enokida","year":"2016","unstructured":"Enokida H, Yoshino H, Matsushita R, et al. The role of microRNAs in bladder cancer. Investig Clin Urol. 2016;57(1):S60-76.","journal-title":"Investig Clin Urol."}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-025-04355-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-04355-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-04355-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T15:04:02Z","timestamp":1769785442000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-025-04355-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,28]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4355"],"URL":"https:\/\/doi.org\/10.1007\/s12672-025-04355-5","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,28]]},"assertion":[{"value":"2 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All patients gave written informed consent for using clinical data in the study in accordance with the Declaration of Helsinki. The study has been approved by the Ethics Committee of the First Affiliated Hospital of Anhui Medical University (PJ2025-10\u201389). Informed consent was obtained from all individual participants included in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"183"}}